JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Handford, S. W.
Right arrow Articles by Smith, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handford, S. W.
Right arrow Articles by Smith, P. K.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Motion Sickness
Journal of Pharmacology And Experimental Therapeutics, Vol. 111, Issue 4, 447-453, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics

DRUGS PREVENTING MOTION SICKNESS AT SEA

S. W. Handford 1, T. E. Cone Jr. 2, Herman I. Chinn 3, and Paul K. Smith 4

1 Department of Physiology, Naval Medical Field Research Laboratory, Camp Lejeune, North Carolina
2 U. S. Naval Hospital, Bethesda, Maryland
3 Department of Pharmacology, USAF School of Aviation Medicine, Randolph AFB, Texas
4 Department of Pharmacology, The George Washington University School of Medicine, Washington, D. C.

Three drugs, scopolamine hydrobromide, Benadryl and Postafene, were reevaluated as preventives of motion sickness. In the doses employed, Benadryl and Postafene afford significant protection with few untoward side effects; scopolamine provides no protection and is conducive to the significant manifestation of unpleasant side effects.

Chloropromazine tested for the first time at sea, gives no significant protection, whereas Lilly preparation 01780, also tested for the first time, is effective at the 0.02 P level.

The incidence of seasickness is again shown to decrease with increasing age and also to correlate with a previous history of motion sickness.

From the standpoint of long-time protection afforded by a single dose, Postafene is most promising, since it gives good protection for at least 24 hours.

Submitted on April 1, 1954




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
D. G. FRIEND and G. A. McLEMORE Jr.
Antiemetic Properties of a New Chlorphenothiazine Derivative, Proclorperazine
Arch Intern Med, May 1, 1957; 99(5): 732 - 735.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
C. R. STEPHEN, S. DENT, and M. BOURGEOIS-GAVARDIN
Control of Nausea and Vomiting: Incidence of Side-Effects
Arch Intern Med, December 1, 1955; 96(6): 794 - 798.
[Abstract] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
L. B. GUTNER, W. J. GOULD, and J. S. HANLEY
Effect of Meclizine Hydrochloride (Bonamine) upon Vestibular Function: Observations with Notes on Its Value in Comparison with Cyclizine Hydrochloride (Marezine) and Dimenhydrinate (Dramamine)
Arch Otolaryngol Head Neck Surg, November 1, 1955; 62(5): 497 - 503.
[Abstract] [PDF]

Home page
 Arch OphthalmolHome page
J. E. HARRIS
PHARMACOLOGY AND TOXICOLOGY
Arch Ophthalmol, August 1, 1955; 54(2): 262 - 299.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.